Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments
暂无分享,去创建一个
R. Knight | A. Arbab | B. R. Achyut | A. Iskander | A. Shankar | A. G. Scicli | R. Ara | A. Scicli
[1] R. Knight,et al. Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks. , 2015, Cancer letters.
[2] P. Wen,et al. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma , 2014, Oncotarget.
[3] I. Simeonova,et al. In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies , 2014, Cellular and Molecular Life Sciences.
[4] I. Simeonova,et al. In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies , 2014, Cellular and Molecular Life Sciences.
[5] A. Arbab,et al. Myeloid Derived Suppressor Cells: Fuel the Fire , 2014, Biochemistry & physiology.
[6] Bhanu P. Jena,et al. Journal of Cellular and Molecular Medicine , 2014, Journal of Cellular and Molecular Medicine.
[7] Xiao-li Zhang,et al. Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. , 2014, Cancer research.
[8] K. Aldape,et al. Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.
[9] R. Sidman,et al. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis , 2013, Proceedings of the National Academy of Sciences.
[10] Stephen L. Brown,et al. Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. , 2013, Translational oncology.
[11] B. R. Achyut. Impact of Microenvironment in Therapy-Induced Neovascularization ofGlioblastoma , 2013 .
[12] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[13] Sarah E. Seton-Rogers. Tumour microenvironment: Means of resistance , 2013, Nature Reviews Cancer.
[14] Zhaoshi Jiang,et al. An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.
[15] Jennie W. Taylor,et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. , 2013, Neuro-oncology.
[16] F. Peale,et al. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment , 2013, Proceedings of the National Academy of Sciences.
[17] J. Heymach,et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. , 2012, Neuro-oncology.
[18] K. Connelly,et al. eNOS deficiency predisposes podocytes to injury in diabetes. , 2012, Journal of the American Society of Nephrology : JASN.
[19] W. Stetler-Stevenson,et al. TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis , 2012, Journal of immunotherapy.
[20] A. Arbab. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. , 2012, Histology and histopathology.
[21] H. Pan,et al. Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. , 2012, Cancer research.
[22] Luca Richeldi,et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.
[23] M. Chamberlain. The paradoxical effect of bevacizumab in the therapy of malignant gliomas , 2011, Neurology.
[24] W. Hickey,et al. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model , 2011, ASN neuro.
[25] N. Heisterkamp,et al. AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo , 2011, Blood cancer journal.
[26] S. Gautam,et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[27] S. Yang,et al. In vivo Tracking of Transplanted Bone Marrow-Derived Mesenchymal Stem Cells in a Murine Model of Stroke by Bioluminescence Imaging. , 2010, Journal of Korean Neurosurgical Society.
[28] E. Seifried,et al. Bone marrow derived cells in the tumour microenvironment contain cells with primitive haematopoietic phenotype , 2010, Journal of cellular and molecular medicine.
[29] C. Patlak,et al. The MRI‐measured arterial input function resulting from a bolus injection of Gd‐DTPA in a rat model of stroke slightly underestimates that of Gd‐[14C]DTPA and marginally overestimates the blood‐to‐brain influx rate constant determined by Patlak plots , 2010, Magnetic resonance in medicine.
[30] A. Karsan,et al. Involvement of endothelial progenitor cells in tumor vascularization. , 2010, Microvascular research.
[31] H. Vogel,et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.
[32] E. Kleinerman,et al. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. , 2010, Cancer research.
[33] Ali S. Arbab,et al. Changes in Vascular Permeability and Expression of Different Angiogenic Factors Following Anti-Angiogenic Treatment in Rat Glioma , 2010, PloS one.
[34] R. Kerbel,et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. , 2009, Cancer research.
[35] E. Radaelli,et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. , 2009, Histology and histopathology.
[36] Y. Meng,et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.
[37] G. Ahn,et al. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature , 2009, Angiogenesis.
[38] P. Wen,et al. Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.
[39] P. Wen,et al. Antiangiogenic therapy in malignant gliomas , 2008, Current opinion in oncology.
[40] R. Knight,et al. Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[42] N. Ferrara,et al. Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.
[43] J. Talmadge,et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. , 2008, Blood.
[44] Arjan W Griffioen,et al. A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors. , 2008, Biochemical and biophysical research communications.
[45] G. Ahn,et al. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. , 2008, Cancer cell.
[46] S. Rafii,et al. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. , 2008, Cancer cell.
[47] R. Knight,et al. Identification of Variations in Blood-Brain Barrier Opening After Cerebral Ischemia by Dual Contrast-Enhanced Magnetic Resonance Imaging and T1sat Measurements , 2008, Stroke.
[48] F. Peale,et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.
[49] S. Kuroda,et al. Role of SDF-1/CXCR4 system in survival and migration of bone marrow stromal cells after transplantation into mice cerebral infarct , 2007, Brain Research.
[50] G. Fuh,et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.
[51] S. Rafii,et al. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. , 2007, Trends in immunology.
[52] R. Tsien,et al. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. , 2007, Cancer research.
[53] D. Scadden,et al. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. , 2006, Cancer research.
[54] David J. Yang,et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.
[55] Fan Zhang,et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes , 2006, Nature Medicine.
[56] Alberto Mantovani,et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.
[57] K. Camphausen,et al. Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. , 2005, Cancer research.
[58] J. Parham,et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[59] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[60] R. Weissleder,et al. Bone marrow-derived lin(-)c-kit(+)Sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. , 2005, Neoplasia.
[61] M. Chopp,et al. Analysis of Combined Treatment of Embolic Stroke in Rat with r-tPA and a GPIIb/IIIa Inhibitor , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[62] M. Pesce,et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. , 2004, Blood.
[63] B. Fingleton,et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.
[64] Geoffrey C Gurtner,et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.
[65] Daniel J Brat,et al. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.
[66] Lian Li,et al. Patlak plots of Gd‐DTPA MRI data yield blood–brain transfer constants concordant with those of 14C‐sucrose in areas of blood–brain opening , 2003, Magnetic resonance in medicine.
[67] Raymond Sawaya,et al. Optimizing outcomes with maximal surgical resection of malignant gliomas. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[68] S. Rafii,et al. Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.
[69] S. Rafii,et al. Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector‐Mediated Elevation of Serum Levels of SDF‐1, VEGF, and Angiopoietin‐1 , 2001, Annals of the New York Academy of Sciences.
[70] Thomas N. Sato,et al. Universal GFP reporter for the study of vascular development , 2000, Genesis.
[71] Daniela Prayer,et al. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. , 2012, Magnetic resonance imaging.
[72] C. Chiang,et al. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model , 2012, Laboratory Investigation.
[73] J.,et al. The New England Journal of Medicine , 2012 .
[74] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[75] M. Hendrix,et al. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. , 2007, The American journal of pathology.
[76] A. Bikfalvi,et al. Tumor angiogenesis , 2020, Advances in cancer research.
[77] G. Sledge,et al. Can tumor angiogenesis be inhibited without resistance? , 2005, EXS.